This content is from: Home

Stronger pharma merger control depends on CCI performance

The Government of India wants to encourage foreign direct investment in the country’s pharmaceutical industry, but not to the detriment of domestic players. And while it sees the Competition Commission of India playing a key role in the control of prices, not everyone believes this will be sufficient

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial